APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Vaccines for Cancer

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Vaccines for Cancer Industry Growth and Trends Forecast to 2032

Report ID 174044870129 December 2025106 pages

Choose your research edition.

Industry ResearchVaccines for Cancer Industry Research Report 2026126 pages · $2,950 USDIndustry Growth & TrendsGlobal Vaccines for Cancer Industry Growth and Trends Forecast to 2032106 pages · $3,450 USDMarket StructureGlobal Vaccines for Cancer Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Vaccines for Cancer Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Vaccines for Cancer Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global Vaccines for Cancer market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Vaccines for Cancer is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Vaccines for Cancer is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Vaccines for Cancer is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Vaccines for Cancer include Ultimovacs, Sellas Life Sciences, OncoPep, Marker Therapeutics, Inc., Immatics, Immatics, Anergis, AmbioPharm and Almac, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Vaccines for Cancer market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Vaccines for Cancer market size, estimates, and forecasts are presented in terms of sales volume (K Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Vaccines for Cancer market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Vaccines for Cancer.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Vaccines for Cancer market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Vaccines for Cancer Market by Company

Ultimovacs

Sellas Life Sciences

OncoPep

Marker Therapeutics, Inc.

Immatics

Immatics

Anergis

AmbioPharm

Almac

ACT

Vaccines for Cancer Segment by Type

Synthetic Polypeptide Vaccines

Recombinant Polypeptide Vaccine

Other

Vaccines for Cancer Segment by Application

Infectious Disease Prevention

Cancer Immunotherapy

Other

Vaccines for Cancer Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Vaccines for Cancer market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Vaccines for Cancer and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Vaccines for Cancer.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Vaccines for Cancer manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Vaccines for Cancer in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Synthetic Polypeptide Vaccines Table 2. Major Company of Recombinant Polypeptide Vaccine Table 3. Major Company of Other Table 4. Global Vaccines for Cancer Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Vaccines for Cancer Sales by Type (2021-2026) & (K Units) Table 6. Global Vaccines for Cancer Sales Market Share in Volume by Type (2021-2026) Table 7. Global Vaccines for Cancer Sales by Type (2021-2026) & (US$ Million) Table 8. Global Vaccines for Cancer Sales Market Share in Value by Type (2021-2026) Table 9. Global Vaccines for Cancer Price by Type (2021-2026) & (US$/Unit) Table 10. Global Vaccines for Cancer Sales by Type (2027-2032) & (K Units) Table 11. Global Vaccines for Cancer Sales Market Share in Volume by Type (2027-2032) Table 12. Global Vaccines for Cancer Sales by Type (2027-2032) & (US$ Million) Table 13. Global Vaccines for Cancer Sales Market Share in Value by Type (2027-2032) Table 14. Global Vaccines for Cancer Price by Type (2027-2032) & (US$/Unit) Table 15. North America Vaccines for Cancer Sales by Type (2021-2026) & (K Units) Table 16. North America Vaccines for Cancer Sales by Type (2021-2026) & (US$ Million) Table 17. Europe Vaccines for Cancer Sales by Type (2021-2026) & (K Units) Table 18. Europe Vaccines for Cancer Sales by Type (2021-2026) & (US$ Million) Table 19. Asia-Pacific Vaccines for Cancer Sales by Type (2021-2026) & (K Units) Table 20. Asia-Pacific Vaccines for Cancer Sales by Type (2021-2026) & (US$ Million) Table 21. Latin America Vaccines for Cancer Sales by Type (2021-2026) & (K Units) Table 22. Latin America Vaccines for Cancer Sales by Type (2021-2026) & (US$ Million) Table 23. Middle East and Africa Vaccines for Cancer Sales by Type (2021-2026) & (K Units) Table 24. Middle East and Africa Vaccines for Cancer Sales by Type (2021-2026) & (US$ Million) Table 25. Vaccines for Cancer Industry Trends Table 26. Vaccines for Cancer Industry Drivers Table 27. Vaccines for Cancer Industry Opportunities and Challenges Table 28. Vaccines for Cancer Industry Restraints Table 29. Global Vaccines for Cancer Sales Revenue by Company (US$ Million) & (2021-2026) Table 30. Global Vaccines for Cancer Revenue Market Share by Company (2021-2026) Table 31. Global Vaccines for Cancer Sales by Company (2021-2026) & (K Units) Table 32. Global Vaccines for Cancer Sales Share by Company (2021-2026) Table 33. Global Vaccines for Cancer Market Price by Company (2021-2026) & (US$/Unit) Table 34. Global Vaccines for Cancer Industry Company Ranking, 2024 VS 2025 VS 2026 Table 35. Global Vaccines for Cancer Major Company Production Sites and Headquarters Table 36. Global Vaccines for Cancer Company, Product Type & Application Table 37. Global Vaccines for Cancer Company Establishment Date Table 38. Global Company Market Concentration Ratio (CR5 and HHI) Table 39. Global Vaccines for Cancer by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 40. Global Vaccines for Cancer Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 41. Global Vaccines for Cancer Sales by Region (2021-2026) & (K Units) Table 42. Global Vaccines for Cancer Sales Market Share in Volume by Region (2021-2026) Table 43. Global Vaccines for Cancer Sales by Region (2021-2026) & (US$ Million) Table 44. Global Vaccines for Cancer Sales Market Share in Value by Region (2021-2026) Table 45. Global Vaccines for Cancer Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 46. Global Vaccines for Cancer Sales by Region (2027-2032) & (K Units) Table 47. Global Vaccines for Cancer Sales Market Share in Volume by Region (2027-2032) Table 48. Global Vaccines for Cancer Sales by Region (2027-2032) & (US$ Million) Table 49. Global Vaccines for Cancer Sales Market Share in Value by Region (2027-2032) Table 50. Global Vaccines for Cancer Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2027-2032) Table 51. Global Vaccines for Cancer Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 52. Global Vaccines for Cancer Sales by Application (2021-2026) & (K Units) Table 53. Global Vaccines for Cancer Sales Market Share in Volume by Application (2021-2026) Table 54. Global Vaccines for Cancer Sales by Application (2021-2026) & (US$ Million) Table 55. Global Vaccines for Cancer Sales Market Share in Value by Application (2021-2026) Table 56. Global Vaccines for Cancer Price by Application (2021-2026) & (US$/Unit) Table 57. Global Vaccines for Cancer Sales by Application (2027-2032) & (K Units) Table 58. Global Vaccines for Cancer Sales Market Share in Volume by Application (2027-2032) Table 59. Global Vaccines for Cancer Sales by Application (2027-2032) & (US$ Million) Table 60. Global Vaccines for Cancer Sales Market Share in Value by Application (2027-2032) Table 61. Global Vaccines for Cancer Price by Application (2027-2032) & (US$/Unit) Table 62. North America Vaccines for Cancer Sales by Application (2021-2026) & (K Units) Table 63. North America Vaccines for Cancer Sales by Application (2021-2026) & (US$ Million) Table 64. Europe Vaccines for Cancer Sales by Application (2021-2026) & (K Units) Table 65. Europe Vaccines for Cancer Sales by Application (2021-2026) & (US$ Million) Table 66. Asia-Pacific Vaccines for Cancer Sales by Application (2021-2026) & (K Units) Table 67. Asia-Pacific Vaccines for Cancer Sales by Application (2021-2026) & (US$ Million) Table 68. Latin America Vaccines for Cancer Sales by Application (2021-2026) & (K Units) Table 69. Latin America Vaccines for Cancer Sales by Application (2021-2026) & (US$ Million) Table 70. Middle East and Africa Vaccines for Cancer Sales by Application (2021-2026) & (K Units) Table 71. Middle East and Africa Vaccines for Cancer Sales by Application (2021-2026) & (US$ Million) Table 72. Ultimovacs Company Information Table 73. Ultimovacs Business Overview Table 74. Ultimovacs Vaccines for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 75. Ultimovacs Vaccines for Cancer Product Portfolio Table 76. Ultimovacs Recent Development Table 77. Sellas Life Sciences Company Information Table 78. Sellas Life Sciences Business Overview Table 79. Sellas Life Sciences Vaccines for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 80. Sellas Life Sciences Vaccines for Cancer Product Portfolio Table 81. Sellas Life Sciences Recent Development Table 82. OncoPep Company Information Table 83. OncoPep Business Overview Table 84. OncoPep Vaccines for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 85. OncoPep Vaccines for Cancer Product Portfolio Table 86. OncoPep Recent Development Table 87. Marker Therapeutics, Inc. Company Information Table 88. Marker Therapeutics, Inc. Business Overview Table 89. Marker Therapeutics, Inc. Vaccines for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 90. Marker Therapeutics, Inc. Vaccines for Cancer Product Portfolio Table 91. Marker Therapeutics, Inc. Recent Development Table 92. Immatics Company Information Table 93. Immatics Business Overview Table 94. Immatics Vaccines for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 95. Immatics Vaccines for Cancer Product Portfolio Table 96. Immatics Recent Development Table 97. Immatics Company Information Table 98. Immatics Business Overview Table 99. Immatics Vaccines for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 100. Immatics Vaccines for Cancer Product Portfolio Table 101. Immatics Recent Development Table 102. Anergis Company Information Table 103. Anergis Business Overview Table 104. Anergis Vaccines for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 105. Anergis Vaccines for Cancer Product Portfolio Table 106. Anergis Recent Development Table 107. AmbioPharm Company Information Table 108. AmbioPharm Business Overview Table 109. AmbioPharm Vaccines for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 110. AmbioPharm Vaccines for Cancer Product Portfolio Table 111. AmbioPharm Recent Development Table 112. Almac Company Information Table 113. Almac Business Overview Table 114. Almac Vaccines for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 115. Almac Vaccines for Cancer Product Portfolio Table 116. Almac Recent Development Table 117. ACT Company Information Table 118. ACT Business Overview Table 119. ACT Vaccines for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 120. ACT Vaccines for Cancer Product Portfolio Table 121. ACT Recent Development Table 122. North America Vaccines for Cancer Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 123. North America Vaccines for Cancer Sales by Country (2021-2026) & (K Units) Table 124. North America Vaccines for Cancer Sales Market Share by Country (2021-2026) Table 125. North America Vaccines for Cancer Sales Forecast by Country (2027-2032) & (K Units) Table 126. North America Vaccines for Cancer Sales Market Share Forecast by Country (2027-2032) Table 127. North America Vaccines for Cancer Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 128. North America Vaccines for Cancer Market Size by Country (2021-2026) & (US$ Million) Table 129. North America Vaccines for Cancer Market Share by Country (2021-2026) Table 130. North America Vaccines for Cancer Market Size Forecast by Country (2027-2032) & (US$ Million) Table 131. North America Vaccines for Cancer Market Share Forecast by Country (2027-2032) Table 132. Europe Vaccines for Cancer Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 133. Europe Vaccines for Cancer Sales by Country (2021-2026) & (K Units) Table 134. Europe Vaccines for Cancer Sales Market Share by Country (2021-2026) Table 135. Europe Vaccines for Cancer Sales Forecast by Country (2027-2032) & (K Units) Table 136. Europe Vaccines for Cancer Sales Market Share Forecast by Country (2027-2032) Table 137. Europe Vaccines for Cancer Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 138. Europe Vaccines for Cancer Market Size by Country (2021-2026) & (US$ Million) Table 139. Europe Vaccines for Cancer Market Share by Country (2021-2026) Table 140. Europe Vaccines for Cancer Market Size Forecast by Country (2027-2032) & (US$ Million) Table 141. Europe Vaccines for Cancer Market Share Forecast by Country (2027-2032) Table 142. Asia-Pacific Vaccines for Cancer Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 143. Asia-Pacific Vaccines for Cancer Sales by Country (2021-2026) & (K Units) Table 144. Asia-Pacific Vaccines for Cancer Sales Market Share by Country (2021-2026) Table 145. Asia-Pacific Vaccines for Cancer Sales Forecast by Country (2027-2032) & (K Units) Table 146. Asia-Pacific Vaccines for Cancer Sales Market Share Forecast by Country (2027-2032) Table 147. Asia-Pacific Vaccines for Cancer Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 148. Asia-Pacific Vaccines for Cancer Market Size by Country (2021-2026) & (US$ Million) Table 149. Asia-Pacific Vaccines for Cancer Market Share by Country (2021-2026) Table 150. Asia-Pacific Vaccines for Cancer Market Size Forecast by Country (2027-2032) & (US$ Million) Table 151. Asia-Pacific Vaccines for Cancer Market Share Forecast by Country (2027-2032) Table 152. Latin America Vaccines for Cancer Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 153. Latin America Vaccines for Cancer Sales by Country (2021-2026) & (K Units) Table 154. Latin America Vaccines for Cancer Sales Market Share by Country (2021-2026) Table 155. Latin America Vaccines for Cancer Sales Forecast by Country (2027-2032) & (K Units) Table 156. Latin America Vaccines for Cancer Sales Market Share Forecast by Country (2027-2032) Table 157. Latin America Vaccines for Cancer Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 158. Latin America Vaccines for Cancer Market Size by Country (2021-2026) & (US$ Million) Table 159. Latin America Vaccines for Cancer Market Share by Country (2021-2026) Table 160. Latin America Vaccines for Cancer Market Size Forecast by Country (2027-2032) & (US$ Million) Table 161. Latin America Vaccines for Cancer Market Share Forecast by Country (2027-2032) Table 162. Middle East and Africa Vaccines for Cancer Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 163. Middle East and Africa Vaccines for Cancer Sales by Country (2021-2026) & (K Units) Table 164. Middle East and Africa Vaccines for Cancer Sales Market Share by Country (2021-2026) Table 165. Middle East and Africa Vaccines for Cancer Sales Forecast by Country (2027-2032) & (K Units) Table 166. Middle East and Africa Vaccines for Cancer Sales Market Share Forecast by Country (2027-2032) Table 167. Middle East and Africa Vaccines for Cancer Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 168. Middle East and Africa Vaccines for Cancer Market Size by Country (2021-2026) & (US$ Million) Table 169. Middle East and Africa Vaccines for Cancer Market Share by Country (2021-2026) Table 170. Middle East and Africa Vaccines for Cancer Market Size Forecast by Country (2027-2032) & (US$ Million) Table 171. Middle East and Africa Vaccines for Cancer Market Share Forecast by Country (2027-2032) Table 172. Key Raw Materials Table 173. Raw Materials Key Suppliers Table 174. Vaccines for Cancer Distributors List Table 175. Vaccines for Cancer Customers List Table 176. Research Programs/Design for This Report Table 177. Authors List of This Report Table 178. Secondary Sources Table 179. Primary Sources List of Figures Figure 1. Vaccines for Cancer Image Figure 2. Global Vaccines for Cancer Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Vaccines for Cancer Market Size (2021-2032) & (US$ Million) Figure 4. Global Vaccines for Cancer Sales (2021-2032) & (K Units) Figure 5. Synthetic Polypeptide Vaccines Image Figure 6. Global Synthetic Polypeptide Vaccines Sales YoY Growth (2021-2032) & (K Units) Figure 7. Recombinant Polypeptide Vaccine Image Figure 8. Global Recombinant Polypeptide Vaccine Sales YoY Growth (2021-2032) & (K Units) Figure 9. Other Image Figure 10. Global Other Sales YoY Growth (2021-2032) & (K Units) Figure 11. Global Vaccines for Cancer Market Size Overview by Type (2021-2032) & (US$ Million) Figure 12. Global Vaccines for Cancer Market Share by Type 2025 VS 2032 Figure 13. North America Vaccines for Cancer Sales Market Share in Volume by Type in 2025 Figure 14. North America Vaccines for Cancer Sales Market Share in Value by Type in 2025 Figure 15. Europe Vaccines for Cancer Sales Market Share in Volume by Type in 2025 Figure 16. Europe Vaccines for Cancer Sales Market Share in Value by Type in 2025 Figure 17. Asia-Pacific Vaccines for Cancer Sales Market Share in Volume by Type in 2025 Figure 18. Asia-Pacific Vaccines for Cancer Sales Market Share in Value by Type in 2025 Figure 19. Latin America Vaccines for Cancer Sales Market Share in Volume by Type in 2025 Figure 20. Latin America Vaccines for Cancer Sales Market Share in Value by Type in 2025 Figure 21. Middle East and Africa Vaccines for Cancer Sales Market Share in Volume by Type in 2025 Figure 22. Middle East and Africa Vaccines for Cancer Sales Market Share in Value by Type in 2025 Figure 23. Global Top 5 and 10 Vaccines for Cancer Players Market Share by Revenue in 2025 Figure 24. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 25. Infectious Disease Prevention Image Figure 26. Global Infectious Disease Prevention Sales YoY Growth (2021-2032) & (K Units) Figure 27. Cancer Immunotherapy Image Figure 28. Global Cancer Immunotherapy Sales YoY Growth (2021-2032) & (K Units) Figure 29. Other Image Figure 30. Global Other Sales YoY Growth (2021-2032) & (K Units) Figure 31. Global Vaccines for Cancer Market Size Overview by Application (2021-2032) & (US$ Million) Figure 32. Global Vaccines for Cancer Market Share by Application 2025 VS 2032 Figure 33. North America Vaccines for Cancer Sales Market Share in Volume by Application in 2025 Figure 34. North America Vaccines for Cancer Sales Market Share in Value by Application in 2025 Figure 35. Europe Vaccines for Cancer Sales Market Share in Volume by Application in 2025 Figure 36. Europe Vaccines for Cancer Sales Market Share in Value by Application in 2025 Figure 37. Asia-Pacific Vaccines for Cancer Sales Market Share in Volume by Application in 2025 Figure 38. Asia-Pacific Vaccines for Cancer Sales Market Share in Value by Application in 2025 Figure 39. Latin America Vaccines for Cancer Sales Market Share in Volume by Application in 2025 Figure 40. Latin America Vaccines for Cancer Sales Market Share in Value by Application in 2025 Figure 41. Middle East and Africa Vaccines for Cancer Sales Market Share in Volume by Application in 2025 Figure 42. Middle East and Africa Vaccines for Cancer Sales Market Share in Value by Application in 2025 Figure 43. North America Vaccines for Cancer Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 44. North America Vaccines for Cancer Sales Share by Country: 2021 VS 2025 VS 2032 Figure 45. North America Vaccines for Cancer Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 46. North America Vaccines for Cancer Market Share by Country: 2021 VS 2025 VS 2032 Figure 47. Europe Vaccines for Cancer Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 48. Europe Vaccines for Cancer Sales Share by Country: 2021 VS 2025 VS 2032 Figure 49. Europe Vaccines for Cancer Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 50. Europe Vaccines for Cancer Market Share by Country: 2021 VS 2025 VS 2032 Figure 51. Asia-Pacific Vaccines for Cancer Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 52. Asia-Pacific Vaccines for Cancer Sales Share by Country: 2021 VS 2025 VS 2032 Figure 53. Asia-Pacific Vaccines for Cancer Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 54. Asia-Pacific Vaccines for Cancer Market Share by Country: 2021 VS 2025 VS 2032 Figure 55. Latin America Vaccines for Cancer Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 56. Latin America Vaccines for Cancer Sales Share by Country: 2021 VS 2025 VS 2032 Figure 57. Latin America Vaccines for Cancer Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Latin America Vaccines for Cancer Market Share by Country: 2021 VS 2025 VS 2032 Figure 59. Middle East and Africa Vaccines for Cancer Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 60. Middle East and Africa Vaccines for Cancer Sales Share by Country: 2021 VS 2025 VS 2032 Figure 61. Middle East and Africa Vaccines for Cancer Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 62. Middle East and Africa Vaccines for Cancer Market Share by Country: 2021 VS 2025 VS 2032 Figure 63. Vaccines for Cancer Value Chain Figure 64. Key Raw Materials Price Figure 65. Manufacturing Cost Structure Figure 66. Vaccines for Cancer Production Mode & Process Figure 67. Direct Comparison with Distribution Share Figure 68. Distributors Profiles Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • Synthetic Polypeptide Vaccines
  • Recombinant Polypeptide Vaccine
  • Other
Applications
  • Infectious Disease Prevention
  • Cancer Immunotherapy
  • Other
Companies covered
  • Ultimovacs
  • Sellas Life Sciences
  • OncoPep
  • Marker Therapeutics, Inc.
  • Immatics
  • Immatics
  • Anergis
  • AmbioPharm
  • Almac
  • ACT

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Vaccines for Cancer Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Vaccines for Cancer Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Vaccines for Cancer Market by Type
  6. 1.3.1 Synthetic Polypeptide Vaccines
  7. 1.3.2 Recombinant Polypeptide Vaccine
  8. 1.3.3 Other
  9. 1.4 Global Vaccines for Cancer Market Size by Type
  10. 1.4.1 Global Vaccines for Cancer Market Size Overview by Type (2021-2032)
  11. 1.4.2 Global Vaccines for Cancer Historic Market Size Review by Type (2021-2026)
  12. 1.4.3 Global Vaccines for Cancer Forecasted Market Size by Type (2027-2032)
  13. 1.5 Key Regions Market Size by Type
  14. 1.5.1 North America Vaccines for Cancer Sales Breakdown by Type (2021-2026)
  15. 1.5.2 Europe Vaccines for Cancer Sales Breakdown by Type (2021-2026)
  16. 1.5.3 Asia-Pacific Vaccines for Cancer Sales Breakdown by Type (2021-2026)
  17. 1.5.4 South America Vaccines for Cancer Sales Breakdown by Type (2021-2026)
  18. 1.5.5 Middle East and Africa Vaccines for Cancer Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Vaccines for Cancer Industry Trends
  2. 2.2 Vaccines for Cancer Industry Drivers
  3. 2.3 Vaccines for Cancer Industry Opportunities and Challenges
  4. 2.4 Vaccines for Cancer Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Vaccines for Cancer Revenue (2021-2026)
  2. 3.2 Global Top Players by Vaccines for Cancer Sales (2021-2026)
  3. 3.3 Global Top Players by Vaccines for Cancer Price (2021-2026)
  4. 3.4 Global Vaccines for Cancer Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Vaccines for Cancer Major Company Production Sites & Headquarters
  6. 3.6 Global Vaccines for Cancer Company, Product Type & Application
  7. 3.7 Global Vaccines for Cancer Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Vaccines for Cancer Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Vaccines for Cancer Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Vaccines for Cancer Tier 1, Tier 2, and Tier 3
4 Vaccines for Cancer Regional Status and Outlook
  1. 4.1 Global Vaccines for Cancer Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Vaccines for Cancer Historic Market Size by Region
  3. 4.2.1 Global Vaccines for Cancer Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Vaccines for Cancer Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Vaccines for Cancer Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Vaccines for Cancer Forecasted Market Size by Region
  7. 4.3.1 Global Vaccines for Cancer Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Vaccines for Cancer Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Vaccines for Cancer Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Vaccines for Cancer by Application
  1. 5.1 Vaccines for Cancer Market by Application
  2. 5.1.1 Infectious Disease Prevention
  3. 5.1.2 Cancer Immunotherapy
  4. 5.1.3 Other
  5. 5.2 Global Vaccines for Cancer Market Size by Application
  6. 5.2.1 Global Vaccines for Cancer Market Size Overview by Application (2021-2032)
  7. 5.2.2 Global Vaccines for Cancer Historic Market Size Review by Application (2021-2026)
  8. 5.2.3 Global Vaccines for Cancer Forecasted Market Size by Application (2027-2032)
  9. 5.3 Key Regions Market Size by Application
  10. 5.3.1 North America Vaccines for Cancer Sales Breakdown by Application (2021-2026)
  11. 5.3.2 Europe Vaccines for Cancer Sales Breakdown by Application (2021-2026)
  12. 5.3.3 Asia-Pacific Vaccines for Cancer Sales Breakdown by Application (2021-2026)
  13. 5.3.4 South America Vaccines for Cancer Sales Breakdown by Application (2021-2026)
  14. 5.3.5 Middle East and Africa Vaccines for Cancer Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Ultimovacs
  2. 6.1.1 Ultimovacs Company Information
  3. 6.1.2 Ultimovacs Business Overview
  4. 6.1.3 Ultimovacs Vaccines for Cancer Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Ultimovacs Vaccines for Cancer Product Portfolio
  6. 6.1.5 Ultimovacs Recent Developments
  7. 6.2 Sellas Life Sciences
  8. 6.2.1 Sellas Life Sciences Company Information
  9. 6.2.2 Sellas Life Sciences Business Overview
  10. 6.2.3 Sellas Life Sciences Vaccines for Cancer Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Sellas Life Sciences Vaccines for Cancer Product Portfolio
  12. 6.2.5 Sellas Life Sciences Recent Developments
  13. 6.3 OncoPep
  14. 6.3.1 OncoPep Company Information
  15. 6.3.2 OncoPep Business Overview
  16. 6.3.3 OncoPep Vaccines for Cancer Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 OncoPep Vaccines for Cancer Product Portfolio
  18. 6.3.5 OncoPep Recent Developments
  19. 6.4 Marker Therapeutics, Inc.
  20. 6.4.1 Marker Therapeutics, Inc. Company Information
  21. 6.4.2 Marker Therapeutics, Inc. Business Overview
  22. 6.4.3 Marker Therapeutics, Inc. Vaccines for Cancer Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Marker Therapeutics, Inc. Vaccines for Cancer Product Portfolio
  24. 6.4.5 Marker Therapeutics, Inc. Recent Developments
  25. 6.5 Immatics
  26. 6.5.1 Immatics Company Information
  27. 6.5.2 Immatics Business Overview
  28. 6.5.3 Immatics Vaccines for Cancer Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Immatics Vaccines for Cancer Product Portfolio
  30. 6.5.5 Immatics Recent Developments
  31. 6.6 Immatics
  32. 6.6.1 Immatics Company Information
  33. 6.6.2 Immatics Business Overview
  34. 6.6.3 Immatics Vaccines for Cancer Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Immatics Vaccines for Cancer Product Portfolio
  36. 6.6.5 Immatics Recent Developments
  37. 6.7 Anergis
  38. 6.7.1 Anergis Company Information
  39. 6.7.2 Anergis Business Overview
  40. 6.7.3 Anergis Vaccines for Cancer Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Anergis Vaccines for Cancer Product Portfolio
  42. 6.7.5 Anergis Recent Developments
  43. 6.8 AmbioPharm
  44. 6.8.1 AmbioPharm Company Information
  45. 6.8.2 AmbioPharm Business Overview
  46. 6.8.3 AmbioPharm Vaccines for Cancer Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 AmbioPharm Vaccines for Cancer Product Portfolio
  48. 6.8.5 AmbioPharm Recent Developments
  49. 6.9 Almac
  50. 6.9.1 Almac Company Information
  51. 6.9.2 Almac Business Overview
  52. 6.9.3 Almac Vaccines for Cancer Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 Almac Vaccines for Cancer Product Portfolio
  54. 6.9.5 Almac Recent Developments
  55. 6.10 ACT
  56. 6.10.1 ACT Company Information
  57. 6.10.2 ACT Business Overview
  58. 6.10.3 ACT Vaccines for Cancer Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 ACT Vaccines for Cancer Product Portfolio
  60. 6.10.5 ACT Recent Developments
7 North America by Country
  1. 7.1 North America Vaccines for Cancer Sales by Country
  2. 7.1.1 North America Vaccines for Cancer Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Vaccines for Cancer Sales by Country (2021-2026)
  4. 7.1.3 North America Vaccines for Cancer Sales Forecast by Country (2027-2032)
  5. 7.2 North America Vaccines for Cancer Market Size by Country
  6. 7.2.1 North America Vaccines for Cancer Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Vaccines for Cancer Market Size by Country (2021-2026)
  8. 7.2.3 North America Vaccines for Cancer Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Vaccines for Cancer Sales by Country
  2. 8.1.1 Europe Vaccines for Cancer Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Vaccines for Cancer Sales by Country (2021-2026)
  4. 8.1.3 Europe Vaccines for Cancer Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Vaccines for Cancer Market Size by Country
  6. 8.2.1 Europe Vaccines for Cancer Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Vaccines for Cancer Market Size by Country (2021-2026)
  8. 8.2.3 Europe Vaccines for Cancer Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Vaccines for Cancer Sales by Country
  2. 9.1.1 Asia-Pacific Vaccines for Cancer Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Vaccines for Cancer Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Vaccines for Cancer Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Vaccines for Cancer Market Size by Country
  6. 9.2.1 Asia-Pacific Vaccines for Cancer Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Vaccines for Cancer Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Vaccines for Cancer Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Vaccines for Cancer Sales by Country
  2. 10.1.1 South America Vaccines for Cancer Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Vaccines for Cancer Sales by Country (2021-2026)
  4. 10.1.3 South America Vaccines for Cancer Sales Forecast by Country (2027-2032)
  5. 10.2 South America Vaccines for Cancer Market Size by Country
  6. 10.2.1 South America Vaccines for Cancer Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Vaccines for Cancer Market Size by Country (2021-2026)
  8. 10.2.3 South America Vaccines for Cancer Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Vaccines for Cancer Sales by Country
  2. 11.1.1 Middle East and Africa Vaccines for Cancer Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Vaccines for Cancer Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Vaccines for Cancer Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Vaccines for Cancer Market Size by Country
  6. 11.2.1 Middle East and Africa Vaccines for Cancer Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Vaccines for Cancer Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Vaccines for Cancer Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Vaccines for Cancer Value Chain Analysis
  2. 12.1.1 Vaccines for Cancer Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Vaccines for Cancer Production Mode & Process
  7. 12.2 Vaccines for Cancer Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Vaccines for Cancer Distributors
  10. 12.2.3 Vaccines for Cancer Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst